Metsera reports first quarter 2025 financial results and continued portfolio progress

Met-097i, a fully biased, monthly, ultra-long acting glp-1 receptor agonist, is in three ongoing vesper phase 2b trials, with data from vesper-1 expected in mid-2025

MTSR Ratings Summary

MTSR Quant Ranking